Skip to main content

Table 2 The characteristics of included studies

From: The effectiveness and safety of LMWH for preventing thrombosis in patients with spinal cord injury: a meta-analysis

Study/year

Patients

Gender (male,%)

Interventions

Cord injury level

Tetraplegia

Paraplegia

AIS

Study design

Cervical

Thoracic

Lumber

A/B

C/D/E

Ahlquist et al. 2020 [16]

79

61.0

LMWH (40 mg daily)/UFH (5000 U twice daily)

49

28

2

-

-

44

46

Retrospective cohort study

Hamidi et al. 2019 [17]

810

58.0

LMWH

98

189

175

-

-

-

-

Retrospective cohort study

DOACs

57

74

95

Worley et al. 2008 [18]

79

49.0

LDUH (heparin 5000 U twice daily)

-

-

-

35

12

24

23

Retrospective cohort study

LMWH (dalteparin 5000 units daily)

25

18

20

23

Spinal Cord Injury Thromboprophylaxis Investigators 2003 [19]

476

81.7

UFH (5000 U every 8 h)

-

-

-

147

73

215

31

Retrospective cohort study

Enoxaparin (30 mg every 12 h)

130

67

191

39

Thumbikat et al. 2002 [20]

173

74.6

Heparin (5000 U twice daily)

36

46

19

-

-

-

-

Retrospective cohort study

Enoxaparin (40mg daily)

38

24

10